title: Roflumilast for severe COPD?
abstract: Estimates suggest that over 3 million people in the UK have chronic obstructive pulmonary disease (COPD).1 Drug management for the condition includes treatments to relieve respiratory symptoms, and prevent and treat acute exacerbations.2,3 ▾Roflumilast (Daxas - Merck Sharp & Dohme) is the first marketed drug in a new class (selective oral phosphodiesterase 4 [PDE4] inhibitors), "aimed at targeting COPD inflammation"4 and licensed as maintenance treatment for severe COPD.5 Here we discuss its place in the management of patients with COPD.
mesh_terms: D000631:Aminopyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000631:Aminopyridines; D001549:Benzamides; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast